임상 한눈에 보기

• 1건의 ClinicalTrials.gov 임상 기록
• 임상시험 탭에서 enrollment 상위 목록을 불러올 수 있습니다
• Phase: PHASE1 · PHASE1, PHASE2
• Status: TERMINATED · COMPLETED
• 주요 endpoint: MTD of Akt inhibitor MK-2206 and lapatinib ditosylate in combination with trastuzumab determined by dose limiting toxicities as measured by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4 · Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) · Proportion of Complete Response Defined to be a CR or CRi Noted as the Objective Status (Phase II)
• 등록 대상자(표본 합산): 약 75명
• 선택한 코호트 보고값: ORR 0.92%
• 핵심: This phase I/II trial studies the side effects and best dose of v-akt murine thymoma viral oncogene homolog 1 (Akt) inhi…

수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.